https://retacompare.com/news/gait-speed-changes-in-obesity-program-with-semaglutide-in-japanese-adults 2026-10-15T00:00:00.000Z RetatrutideCompare en 2026-10-15T00:00:00.000Z Gait Speed Changes in Obesity Program with Semaglutide in Japanese Adults Patient Experiences, Retatrutide https://retacompare.com/news/overview-of-retatrutide-s-weight-loss-potential-by-2026 2026-10-14T20:17:52.000Z RetatrutideCompare en 2026-10-14T20:17:52.000Z Overview of Retatrutide's Weight Loss Potential by 2026 Weight Loss, Retatrutide https://retacompare.com/news/challenges-in-adapting-adult-obesity-drugs-for-pediatric-use 2026-10-14T18:00:38.352Z RetatrutideCompare en 2026-10-14T18:00:38.352Z Challenges in Adapting Adult Obesity Drugs for Pediatric Use Weight Loss, Retatrutide https://retacompare.com/news/impact-of-glp-1-agonists-on-spine-surgery-outcomes-reviewed 2026-10-14T18:00:38.343Z RetatrutideCompare en 2026-10-14T18:00:38.343Z Impact of GLP-1 Agonists on Spine Surgery Outcomes Reviewed Clinical Trials, Retatrutide https://retacompare.com/news/retatrutide-potential-availability-of-new-weight-loss-drug-explored 2026-10-14T17:33:49.000Z RetatrutideCompare en 2026-10-14T17:33:49.000Z Retatrutide: Potential Availability of New Weight-Loss Drug Explored Market News, Retatrutide https://retacompare.com/news/verdiva-halts-oral-glp-1-study-citing-market-shifts 2026-10-14T12:54:35.000Z RetatrutideCompare en 2026-10-14T12:54:35.000Z Verdiva Halts Oral GLP-1 Study Citing Market Shifts Market News, Retatrutide